Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Ridgeback Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Ridgeback Capital

Ridgeback Capital

Operating

NYC-based Ridgeback Capital is a financial services firm specializing in healthcare hedge funds.

Location
New York City, NY, US
Founded
2006
Firm
Compare
Portfolio
Employees
Website

Ridgeback Capital is a New York City-based healthcare hedge fund specializing in life science investments. The firm focuses on investing in biotechnology, pharmaceutical, and medical technology companies across various stages of development, from early-stage startups to established public companies.

Notable portfolio companies include Freenome, Caribou Biosciences, and Butterfly Network. Ridgeback Capital's investment strategy emphasizes innovative healthcare solutions and breakthrough technologies. The firm's expertise in the life sciences sector allows it to provide valuable insights and support to its portfolio companies, helping them navigate the complex healthcare landscape and accelerate their growth.

Ridgeback Capital - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments19
Current Portfolio Count15
Total Portfolio Exits0

Top Investment Stages

Series B7 (41.2%)
Series A4 (23.5%)
Series C3 (17.6%)
Post Ipo Equity2 (11.8%)
Series D1 (5.9%)

Stage Mix

Series B 41%Series A 24%Series C 18%Post Ipo Equity 12%Series D 6%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Crisp logo

Crisp

Freenome logo

Freenome

Arbor Biotechnologies logo

Arbor Biotechnologies

Garuda Therapeutics logo

Garuda Therapeutics

TwinStrand Biosciences logo

TwinStrand Biosciences

Acepodia logo

Acepodia

Caribou Biosciences logo

Caribou Biosciences

Viracta Therapeutics logo

Viracta Therapeutics

Butterfly Network logo

Butterfly Network

Reverie Labs logo

Reverie Labs

Senti Biosciences logo

Senti Biosciences

Aro Biotherapeutics logo

Aro Biotherapeutics

4D Molecular Therapeutics logo

4D Molecular Therapeutics

Precision BioSciences logo

Precision BioSciences

Selecta Biosciences logo

Selecta Biosciences

Bellicum Pharmaceuticals logo

Bellicum Pharmaceuticals

Microbia logo

Microbia

Ridgeback Capital - Similar Investment Firms

Ridgeview Asset Management Partners logo

Ridgeview Asset Management Partners

ridgeviewasset.com

Peak Ridge Capital logo

Peak Ridge Capital

Ridge Capital Partners logo

Ridge Capital Partners

ridgecapital.com

Ridgeline Capital Partners logo

Ridgeline Capital Partners

ridgelinecp.com

Ridge Ventures logo

Ridge Ventures

ridge.vc

Ridgepeak Partners logo

Ridgepeak Partners

Elm Ridge Management logo

Elm Ridge Management

Ridgeline Ventures logo

Ridgeline Ventures

ridgelinevc.com

Stone Ridge Asset Management logo

Stone Ridge Asset Management

stoneridgeam.com

Ditch Plains Capital Management logo

Ditch Plains Capital Management

Grouse Ridge Capital logo

Grouse Ridge Capital

Ridgewood Capital logo

Ridgewood Capital

Spring Ridge Ventures logo

Spring Ridge Ventures

Pathocapital logo

Pathocapital

Global BioAccess Fund logo

Global BioAccess Fund

Ridgeback Capital - Classification

NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 5 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
SIC
  • 6000Depository Institutions
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified